Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02816983 · ClinicalTrials.gov registry record
SBRT for Oligometastatic Castration-Refractory Prostate Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 89
- Enrollment target
NCT02816983: Completed study, sponsored by Mayo Clinic.
NCT02816983 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02816983 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions. Patients with \<=3 metastatic lesions will receive stereotactic body radiotherapy (SBRT) as definitive treatment. Blood draws will be taken to monitor the development of anti-prostate cancer immunity
Interventions
- RADIATION SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2016-03 |
| Est. Completion | 2022-01-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02816983
The ClinicalTrials.gov registry entry for NCT02816983 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SBRT is the first listed.
NCT02816983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02816983 about?
NCT02816983 is a clinical study titled "SBRT for Oligometastatic Castration-Refractory Prostate Cancer". Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions. Patients with \<=3 metastatic lesions will receive stereotactic body radiotherapy (SBRT) as definitive treatment. Bl...
What is the current status of trial NCT02816983?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2016-03. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT02816983?
The interventions under investigation include: SBRT (RADIATION).
Who is sponsoring clinical trial NCT02816983?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.